Endocrine Abstracts

With the wide-spread use of abiraterone/enzalutamide for CRPC, there is an urgent need to understand and reverse resistance to these treatments. Studies have implicated glucocorticoid receptor (GR) as activating androgen receptor (AR) signalling and driving resistance. Here we studied progesterone receptor (PR), which is phylogenetically most closely related to the AR. We first used digital droplet PCR in prostate cancer (PCa) cell lines and observed >10 times higher level...

Cognitive dysfunctions, observed in the course of thyroid diseases (hyper- and hypothyroidism), have – in the recent years – been the subject of interest for many research teams. Even mild disorders of thyroid functionality are associated with hormone concentration changes which affect the general mood and cognitive functions. The efficiency of cognitive functions, which allow the man’s adaptation to environment al conditions, is determined by the activities of ...

Objective: Previous studies indicated that two glucocorticoid receptor gene polimorphisms bclI and N363S (GC-S) are associated with increased sensitivity to glucocorticoids and two other polymorphisms 9β and ER22/23EK (GC-I) are related to decreased sensitivity to glucocorticoids. The aim of the study was to determine whether these genetic changes can effect on the occurence of steroid-induced adverse events.Methods: One hundred and fifty p...

Introduction: Interferon alpha (IFN alpha) is a cytokine with pleiotropic effects and via different pathways influences secretion of certain cytokines and hormones. Growth Hormone (GH) secreted from the pituitary has its physiological effects on various target tissues. The question is how IFN alpha administered in various type of diseases influences GH secretion. This study investigated acute effect of IFN-alpha on GH mRNA expression in rat anterior pituitary<p class="abst...

Introduction: Patients with connective tissue diseases are susceptible to the occurrence of side-effects of long term treatment with low-dose glucocorticoids as these medications often cannot be withdrawn due to exacerbation of the underlying disease. The new-onset of glucose metabolism impairment is not considered common in patients treated with low-dose glucocorticoids and the risk factors are thought to be the same as in general population: increasing age, obesity or family...